Patients disposition. (IMAGE)

Maximum Academic Press

Patients disposition.

Caption

Cohort 1, osimertinib monotherapy. Cohort 2, a combination of osimertinib and savolitinib therapy. The cutoff date: May 28, 2024. FAS, Full Analysis Set; PD, Progressive disease. [1] Patients with MET amplification and/or overexpression identified by prospective tumor tissue testing (FISH, NGS, or IHC) were referred to participate in this study. [2] Two patients in Cohort 1 who PD and confirmed MET aberrant positive after 1 L treatment had crossover to Cohort 2.

Credit

Nature Communications

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

License

CC BY-NC-ND

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.